Suppr超能文献

潜在的肝脏疾病而非肿瘤因素可预测肝细胞癌切除术后的长期生存情况。

Underlying liver disease, not tumor factors, predicts long-term survival after resection of hepatocellular carcinoma.

作者信息

Bilimoria M M, Lauwers G Y, Doherty D A, Nagorney D M, Belghiti J, Do K A, Regimbeau J M, Ellis L M, Curley S A, Ikai I, Yamaoka Y, Vauthey J N

机构信息

Department of Surgical Oncology, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Box 106, Houston, TX 77030, USA.

出版信息

Arch Surg. 2001 May;136(5):528-35. doi: 10.1001/archsurg.136.5.528.

Abstract

HYPOTHESIS

A subset of patients can be identified who will survive without recurrence beyond 5 years after hepatic resection for hepatocellular carcinoma (HCC).

DESIGN

A retrospective review of a multi-institutional database of 591 patients who had undergone hepatic resection for HCC and on-site reviews of clinical records and pathology slides.

SETTING

All patients had been treated in academic referral centers within university-based hospitals.

PATIENTS

We identified 145 patients who had survived for 5 years or longer after hepatic resection for HCC.

MAIN OUTCOME MEASURES

Clinical and pathologic factors, as well as scoring of hepatitis and fibrosis in the surrounding liver parenchyma, were assessed for possible association with survival beyond 5 years and cause of death among the 145 five-year survivors.

RESULTS

Median additional survival duration longer than 5 years was 4.1 years. Women had significantly longer median additional survival durations than did men (81 months vs 38 months, respectively, after the 5-year mark) (P =.008). Surgical margins, type of resection, an elevated preoperative alpha-fetoprotein level, and the presence of multiple tumors or microscopic vascular invasion had no bearing on survival longer than 5 years. However, patients who survived for 5 years who also had normal underlying liver or minimal fibrosis (score, 0-2) at surgery had significantly longer additional survival than did patients with moderate fibrosis (score, 3-4) or severe fibrosis/cirrhosis (score, 5-6) (P<.001).

CONCLUSIONS

Death caused by HCC is rare beyond 5 years after resection of HCC in the absence of fibrosis or cirrhosis. The data suggest that chronic liver disease acts as a field of cancerization contributing to new HCC. These patients may benefit from therapies directed at the underlying liver disease.

摘要

假设

可以识别出一部分肝细胞癌(HCC)肝切除术后5年以上无复发存活的患者。

设计

对591例行HCC肝切除术患者的多机构数据库进行回顾性分析,并对临床记录和病理切片进行现场评估。

地点

所有患者均在大学附属医院的学术转诊中心接受治疗。

患者

我们识别出145例HCC肝切除术后存活5年或更长时间的患者。

主要观察指标

评估临床和病理因素,以及周围肝实质的肝炎和纤维化评分,以确定其与145例5年存活者5年以上生存期及死亡原因的可能关联。

结果

超过5年的中位额外生存期为4.1年。女性的中位额外生存期明显长于男性(5年标记后分别为81个月和38个月)(P = 0.008)。手术切缘、切除类型、术前甲胎蛋白水平升高以及存在多个肿瘤或微小血管侵犯与超过5年的生存期无关。然而,手术时肝基础正常或纤维化程度轻微(评分0 - 2)的5年存活患者的额外生存期明显长于中度纤维化(评分3 - 4)或重度纤维化/肝硬化(评分5 - 6)的患者(P < 0.001)。

结论

在无纤维化或肝硬化的情况下,HCC切除术后5年以上因HCC导致死亡很少见。数据表明,慢性肝病作为一个癌化区域促成新的HCC。这些患者可能从针对基础肝病的治疗中获益。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验